NEW YORK (GenomeWeb) – Agilent Technologies' motion to amend its complaint in a lawsuit it filed against Twist Bioscience in 2016 was granted, according to documents Twist filed today with the US Securities and Exchange Commission.
The Santa Clara Superior Court also denied Agilent's motion to limit the discovery that Twist and Twist CEO Emily Leproust could seek in the case and set a date for the trial of Feb. 24, 2020.